 previous article in this issue | next article in this issue  |
|
Document Details : Title: Clinical implications of JAK2 mutations in myeloproliferative disorders Author(s): KNOOPS L, HERMANS C, FERRANT A, CONSTANTINESCU SN Journal: Acta Clinica Belgica Volume: 63 Issue: 2 Date: 2008 Pages: 93-98 DOI: 10.2143/ACB.63.2.1002550 Abstract : The V617F mutation of JAK2 is the key molecular event in 90% of polycythaemia vera (PV), 50% of essential thrombocythaemia (ET) and 50% of primary myelofi brosis (PMF). JAK2 exon 12 and MPLW515 mutations are less frequent. Because JAK2 V617F is specific for myeloid neoplasms, and because it can be detected in peripheral blood granulocytes, it offers a powerful tool that facilitates the diagnosis of these BCR-ABL negative myeloproliferative disorders. These discoveries provide the rationale for a revision of the current WHO diagnostic criteria for PV, ET and PMF and could ultimately lead to the development of a specific targeted therapy. |
